BACKGROUND: The study was conducted to investigate continuous daily levonorgestrel 90 mcg/ethinyl estradiol 20 mcg (LNG/EE) on premenstrual dysphoric disorder (PMDD). STUDY DESIGN: In this multicenter, randomized, double-blind, placebo-controlled study, women with PMDD receivedLNG/EE (n=186) orplacebo (n=181) daily for 112 days and completed the Daily Record of Severity of Problems (DRSP). RESULTS:Mean DRSP change from baseline to late luteal phase was significantly greater with LNG/EE than placebo at the late luteal phase of the first estimated cycle (-30.52±1.73 [SE] vs. -22.47±1.77; p<.001) and the worst 5 days during the last on-therapy estimated cycle (-26.77±1.83 vs. -20.89±1.82; p=.016). Other primary end points were not statistically significant. Significantly more subject taking LNG/EE (52%) than placebo (40%) responded (≥50% improvement in the DRSP 7-day late luteal phase score and Clinical Global Impression of Severity score of ≥1 improvement) at last on-therapy cycle (p=.025). CONCLUSIONS: Continuous daily LNG 90 mcg/EE 20 mcg was well tolerated and may be useful for managing the physical, psychological and behavioral symptoms and loss of work productivity related to PMDD.
RCT Entities:
BACKGROUND: The study was conducted to investigate continuous daily levonorgestrel 90 mcg/ethinyl estradiol 20 mcg (LNG/EE) on premenstrual dysphoric disorder (PMDD). STUDY DESIGN: In this multicenter, randomized, double-blind, placebo-controlled study, women with PMDD received LNG/EE (n=186) or placebo (n=181) daily for 112 days and completed the Daily Record of Severity of Problems (DRSP). RESULTS: Mean DRSP change from baseline to late luteal phase was significantly greater with LNG/EE than placebo at the late luteal phase of the first estimated cycle (-30.52±1.73 [SE] vs. -22.47±1.77; p<.001) and the worst 5 days during the last on-therapy estimated cycle (-26.77±1.83 vs. -20.89±1.82; p=.016). Other primary end points were not statistically significant. Significantly more subject taking LNG/EE (52%) than placebo (40%) responded (≥50% improvement in the DRSP 7-day late luteal phase score and Clinical Global Impression of Severity score of ≥1 improvement) at last on-therapy cycle (p=.025). CONCLUSIONS: Continuous daily LNG 90 mcg/EE 20 mcg was well tolerated and may be useful for managing the physical, psychological and behavioral symptoms and loss of work productivity related to PMDD.
Authors: Tory A Eisenlohr-Moul; Susan S Girdler; Jacqueline L Johnson; Peter J Schmidt; David R Rubinow Journal: Depress Anxiety Date: 2017-07-17 Impact factor: 6.505
Authors: Peter J Schmidt; Pedro E Martinez; Lynnette K Nieman; Deloris E Koziol; Karla D Thompson; Linda Schenkel; Paul G Wakim; David R Rubinow Journal: Am J Psychiatry Date: 2017-04-21 Impact factor: 18.112
Authors: Kimberly A Yonkers; Brianna Cameron; Ralitza Gueorguieva; Margaret Altemus; Susan G Kornstein Journal: J Womens Health (Larchmt) Date: 2016-11-17 Impact factor: 2.681
Authors: Tracy Nevatte; Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen W Freeman; Uriel Halbreich; Khalid Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; David Rubinow; Peter Schmidt; Meir Steiner; John Studd; Inger Sundström-Poromaa; Kimberly Yonkers Journal: Arch Womens Ment Health Date: 2013-04-27 Impact factor: 3.633
Authors: Christopher R Beam; Patrizia Pezzoli; Jane Mendle; S Alexandra Burt; Michael C Neale; Steven M Boker; Pamela K Keel; Kelly L Klump Journal: Dev Psychopathol Date: 2020-10-29